Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.

Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG.

PLoS One. 2013;8(3):e59735. doi: 10.1371/journal.pone.0059735. Epub 2013 Mar 21.

2.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG.

J Alzheimers Dis. 2011;24(2):315-25. doi: 10.3233/JAD-2011-101809.

3.

Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab.

Roher AE, Maarouf CL, Kokjohn TA, Belden C, Serrano G, Sabbagh MS, Beach TG.

Am J Neurodegener Dis. 2016 Aug 26;5(4):158-170. eCollection 2016.

4.

Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.

Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castaño EM, Sabbagh MN, Beach TG, Roher AE.

PLoS One. 2011;6(11):e27291. doi: 10.1371/journal.pone.0027291. Epub 2011 Nov 7.

5.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Review.

PMID:
22339463
6.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
7.

Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat.

Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, Belden C, Liebsack C, Jacobson SA, Sabbagh MN, Beach TG.

Am J Neurodegener Dis. 2014 Dec 5;3(3):115-33. eCollection 2014.

8.

Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology.

Attems J, Lintner F, Jellinger KA.

Acta Neuropathol. 2004 Apr;107(4):283-91. Epub 2004 Feb 20. Erratum in: Acta Neuropathol (Berl). 2004 May;107(5):479-80.

PMID:
14986026
9.

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

Brain. 2008 Dec;131(Pt 12):3299-310. doi: 10.1093/brain/awn261. Epub 2008 Oct 25.

PMID:
18953056
10.

Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy.

Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, Nicoll JA.

Acta Neuropathol. 2014 Dec;128(6):777-89. doi: 10.1007/s00401-014-1340-9. Epub 2014 Sep 7.

PMID:
25195061
11.

[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients.

Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B.

Neurochem Int. 2009 May-Jun;54(5-6):347-57. doi: 10.1016/j.neuint.2008.12.016. Epub 2008 Dec 30.

PMID:
19162107
12.

APOE and AβPP gene variation in cortical and cerebrovascular amyloid-β pathology and Alzheimer's disease: a population-based analysis.

Peuralinna T, Tanskanen M, Mäkelä M, Polvikoski T, Paetau A, Kalimo H, Sulkava R, Hardy J, Lai SL, Arepalli S, Hernandez D, Traynor BJ, Singleton A, Tienari PJ, Myllykangas L.

J Alzheimers Dis. 2011;26(2):377-85. doi: 10.3233/JAD-2011-102049.

13.

Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.

Wang HC, Yu YZ, Liu S, Zhao M, Xu Q.

Vaccine. 2016 Apr 4;34(15):1758-66. doi: 10.1016/j.vaccine.2016.02.056. Epub 2016 Mar 2.

PMID:
26945100
14.

[Aβ immunotherapy for Alzheimer's disease].

Sakai K, Yamada M.

Brain Nerve. 2013 Apr;65(4):461-8. Review. Japanese.

PMID:
23568994
15.

Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.

Miners JS, Clarke P, Love S.

Brain Pathol. 2017 May;27(3):305-313. doi: 10.1111/bpa.12392. Epub 2016 Jul 8.

PMID:
27248362
16.

Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.

Merlini M, Wanner D, Nitsch RM.

Acta Neuropathol. 2016 May;131(5):737-52. doi: 10.1007/s00401-016-1560-2. Epub 2016 Mar 17.

17.

Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.

Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G, Colombo A, Lanzani F, Piscosquito G, Carriero MR, Giaccone G, Tagliavini F, Ferrarese C, DiFrancesco JC.

Ann Neurol. 2013 Apr;73(4):449-58. doi: 10.1002/ana.23857. Epub 2013 Apr 26.

PMID:
23625526
18.

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

Tayeb HO, Murray ED, Price BH, Tarazi FI.

Expert Opin Biol Ther. 2013 Jul;13(7):1075-84. doi: 10.1517/14712598.2013.789856. Epub 2013 Apr 10. Review.

PMID:
23574434
19.

Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Wilcock DM, Colton CA.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):50-64. Review.

20.

Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.

Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, Pickering RM, Nicoll JA, Holmes C, Hugon J, Boche D.

J Pathol. 2015 Apr;235(5):721-30. doi: 10.1002/path.4491. Epub 2015 Jan 7.

PMID:
25430817

Supplemental Content

Support Center